Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...
Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...
6don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on ...
Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...
The NHS rollout of appetite suppressing injections has been thrown into doubt after what is believed to be the first confirmed death linked to the controversial drugs ...
The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback